Could First-Mover Advantage Make Curetis Ripe For The Picking By Dx Players?

 
• By Tina Tan
  
Ripe pears on the tree against the blue sky.
With US approval of Unyvero imminent, is German molecular diagnostics firm Curetis ripe for M&A?

More from In Vitro Diagnostics

More from Diagnostics